S. 1607: Improving National Safety, Public health, Ethics, and Clinical Trials Act

This bill, known as the Improving National Safety, Public Health, Ethics, and Clinical Trials Act (or INSPECT Act), aims to enhance the oversight of three major public health agencies in the United States: the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA). Here’s what the bill would do:

Establishment of Inspectors General

The bill proposes the creation of Inspector General (IG) positions for each of the following:

• National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• Food and Drug Administration (FDA)

These IGs would be responsible for overseeing the activities and operations of their respective agencies to ensure accountability, effectiveness, and integrity in their functions.

Appointment Process

The bill mandates that the President appoint individuals to these Inspector General positions within one year of the bill's enactment. The appointments will follow specific guidelines set forth in U.S. law regarding government officials.

Budgetary Compliance

Importantly, the implementation of this act will not require additional funding. Instead, it stipulates that the necessary funding for the operations of these new Inspector General offices will come from existing appropriations allocated to the Office of the Inspector General within the Department of Health and Human Services. In other words, the bill is designed to use already allocated funds rather than seek new resources.

Objectives of the Bill

The overarching goal of the INSPECT Act is to improve national safety and public health ethics through better oversight and transparency in health and safety practices among these key federal health agencies. By establishing dedicated inspectors general, the act seeks to reinforce public trust in public health initiatives and regulatory processes.

Relevant Companies

None found